Last updated on July 2019

Generalized Anxiety Disorder Research Study


Brief description of study

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo in subjects with Generalized Anxiety Disorder.

Qualified participants may be involved for up to 34 weeks and visit the research center 11 times.  At the first visit, qualified participants will enter a screening period.   After the initial screening period participants will receive either the study medication or a placebo for up to 8 weeks and visit the research center 5 times.

An optional six-month extension may be available after completion of the 8 week study period.  In this extension, all participants would receive the study medication and visit the research office 4  times. Two weeks after the last dose of study medication participants return to the office for a follow-up visit.

 

Clinical Study Identifier: TX224557

Find a site near you

Start Over

Summit Research Network, Inc.

2701 NW Vaughn Street, Suite 350 Portland, OR USA
  Connect »